SavedAdd your journal

Journals / European Journal of Therapeutics / 2019 / Cilt: 25 - Sayı: 1

Can the Prognosis of Diffuse Large B-Cell Lymphoma be Predicted by a Simple CBC Count?

Handan HAYDAROĞLU ŞAHİN
Pages
76–81
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The 5-year overall survival (OS) was 37.1%, and 78.9% in the high NLR group, and low NLR group, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we aimed to develop a new prognostic model using the neutrophil-to-lymphocyte ratio (NLR) and defined prognostic indexes to improve the results in patients with diffuse large B-cell lymphoma (DLBCL).
📊
Key Findings & Data:Methods: The data of 340 newly diagnosed patients with DLBCL, who underwent at least two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), were evaluated retrospectively.
💡
Conclusion & Impact:Results: The 5-year overall survival (OS) was 37.1%, and 78.9% in the high NLR group, and low NLR group, respectively.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we aimed to develop a new prognostic model using the neutrophil-to-lymphocyte ratio (NLR) and defined prognostic indexes to improve the results in patients with diffuse large B-cell lymphoma (DLBCL). Methods: The data of 340 newly diagnosed patients with DLBCL, who underwent at least two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), were evaluated retrospectively. A receiver operating characteristic (ROC) curve analysis was used to determine the NLR cut-off value. The NLR cut-off value was 4.76. In the study, a total of 231 patients (67.9%) were in the low NLR ≤4.76 group, while 109 patients (32.1%) were in the high NLR (NLR >4.76) group. Results: The 5-year overall survival (OS) was 37.1%, and 78.9% in the high NLR group, and low NLR group, respectively. A high pre-treatment NLR was associated with a worse OS and progression-free survival (PFS) (both p

🔖

Cite This Article

ŞAHİN, H. H. (2022). Can the Prognosis of Diffuse Large B-Cell Lymphoma be Predicted by a Simple CBC Count?. European Journal of Therapeutics, Cilt: 25 - Sayı: 1, 76–81. https://ajindex.com/articles/512265

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control 2012; 19: 204-13.
  2. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-7.
  3. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26(Suppl 5): v116-25. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987-94.
  4. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61.
  5. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123: 837-42.
  6. Jia B, Shi Y, Kang S, Yang S, Hu S, Li Y, et al. Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma. Chin J Cancer Res 2015; 27: 516-23.
  7. Wang J, Zhou M, Wang X, Xu J, Chen B, Ouyang J. Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP. Clin Chim Acta 2016; 459: 150-4.
  8. Yan-Li L, Kang-Sheng G, Yue-Yin P, Yang J, Zhi-Min Z. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leuk Res 2014; 38: 323-8. 10. Miyashita K, Tomita N, Taguri M, Suzuki T, Ishiyama Y, Ishii Y, et al. Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. Leuk Res 2015; pii: S01452126(15)30368-4. 11. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, et al. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 2016; 175: 290-9. 12. Kim DH,